menu
    • menu
    [{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"7HP349","moa":"||Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"7 Hills Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"7 Hills Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Frontage Clinical Services","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ Frontage Clinical Services","highestDevelopmentStatusID":"7","companyTruncated":"7 Hills Pharma \/ Frontage Clinical Services"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"7 Hills Pharma \/ Undisclosed"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Alintegimod","moa":"||Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"7 Hills Pharma \/ Undisclosed"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"7 Hills Pharma \/ Undisclosed"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"7 Hills Pharma \/ Undisclosed"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Alintegimod","moa":"||Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"7 Hills Pharma \/ Undisclosed"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"7 Hills Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"7 Hills Pharma \/ CPRIT"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Texas Heart Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ Texas Heart Institute","highestDevelopmentStatusID":"6","companyTruncated":"7 Hills Pharma \/ Texas Heart Institute"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"7 Hills Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"7 Hills Pharma \/ Undisclosed"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"7 Hills Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"7 Hills Pharma \/ Undisclosed"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"7 Hills Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"7 Hills Pharma \/ Undisclosed"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"7 Hills Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"7 Hills Pharma \/ Undisclosed"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"7HP935","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"7 Hills Pharma \/ CPRIT","highestDevelopmentStatusID":"4","companyTruncated":"7 Hills Pharma \/ CPRIT"}]

    Find Clinical Drug Pipeline Developments & Deals by 7 Hills Pharma

    Menu

    7 Hills Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alintegimod,Ipilimumab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            7 Hills Pharma Safely Doses First Patient in Alintegimod Trial for Solid Tumors

                            Details : 7HP349 (alintegimod), an integrin-targeted agonist, is being investigated in combination with ipililumab and nivolumab in cancer patients who are resistant to PD-1 treatments.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 03, 2024

                            Lead Product(s) : Alintegimod,Ipilimumab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 7HP935

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : CPRIT

                            Deal Size : $4.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            7 Hills Pharma Receives $4.7MM Grant for Cell/Gene Therapy Technology in the Clinic

                            Details : 7 Hills will advance 7HP935, the Company’s lead first-in-class small molecule to augment CGT, through a Phase I clinical trial.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 03, 2024

                            Lead Product(s) : 7HP935

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : CPRIT

                            Deal Size : $4.7 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alintegimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherapy

                            Details : Alintegimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 12, 2024

                            Lead Product(s) : Alintegimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alintegimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : CPRIT

                            Deal Size : $13.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding

                            Details : The fundings will be used to advance 7HP349 (alintegimod), its first-in-class oral selective integrin activator into a Phase 1b/2a clinical trial in patients who are resistant to PD-1-based therapies.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 22, 2023

                            Lead Product(s) : Alintegimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : CPRIT

                            Deal Size : $13.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DNA Vaccine,Alintegimod

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            7 Hills Pharma Receives $3MM SBIR Grant from NIAID to Accelerate Novel Vaccine Combination Against Chagas Dise...

                            Details : DNA-based vaccine to protect against Tc infection, which was tested in preclinical models in combination with 7HP’s lead, oral immunostimulant. Results of this initial study, demonstrated that the combination therapy was effective in both prophylactic ...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            August 01, 2022

                            Lead Product(s) : DNA Vaccine,Alintegimod

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alintegimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            7 Hills Pharma Expands Pioneering Patent Portfolio With New Claims Covering Innovative Combination Therapies

                            Details : 7HP349 is 7HP’s lead, clinical-stage integrin agonist. It is a first-in-class, orally delivered small molecule that safely and selectively activates the integrins LFA-1 and VLA-4 to augment the antigen-specific immune response.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 09, 2022

                            Lead Product(s) : Alintegimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alintegimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Texas Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors

                            Details : 7HP349 is 7HP’s lead, clinical-stage integrin agonist. It is a first-in-class, orally delivered small molecule that safely and selectively activates the integrins LFA-1 and VLA-4 to augment the antigen-specific immune response.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 18, 2022

                            Lead Product(s) : Alintegimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Texas Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alintegimod,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            7 Hills Pharma’s Clinical-stage Novel Immunostimulant 7HP349 Granted FDA Fast Track Designation for Anti-PD-...

                            Details : 7HP349, an allosteric activator of integrins VLA-4 and LFA-1, used in combination with immunotherapy improve effectiveness of potentially any immunotherapeutic, including, but not limited to immune checkpoint inhibitors and infectious disease vaccines.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 08, 2022

                            Lead Product(s) : Alintegimod,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alintegimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            7 Hills Pharma Announces First Healthy Volunteers Dosed in Landmark Phase 1 Trial of Immunostimulant to Improv...

                            Details : 7HP349 is designed to activate integrins, enhancing cell adhesion for stronger immune responses to vaccinations, such as those for COVID-19 and influenza, and immuno-oncology drugs, such as checkpoint inhibitors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 09, 2020

                            Lead Product(s) : Alintegimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            7 Hills Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alintegimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Frontage Clinical Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects

                            Details : 7HP349 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 11, 2020

                            Lead Product(s) : Alintegimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Frontage Clinical Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth